Inhibitory effects of BAY X 7195, a CYS leukotriene 1 receptor antagonist, on allergen-induced asthmatic responses

Annals of Allergy, Asthma and Immunology

Volumn 79, Issue 2, 1997, Pages 155-161

  Boulet, Louis Philippe ^a,c   Turcotte, Hélène ^a   Laviolette, Michel ^d   Côté, Johanne ^a   Wyile, Geraldine ^b   Bologa, Monica ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b Bayer Canada   (Canada)

^c LAVAL UNIVERSITY   (Canada)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CARBOXYPHENYLTHIO) 7 [4 (4 PHENOXYBUTOXY)PHENYL] 5 HEPTENOIC ACID; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0030850604     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)63103-1     Document Type: Article

References (18)

1. Henderson WR Jr. Eicosanoids and platelet-activating factor in allergic respiratory diseases. Am Rev Respir Dis 1991;143:S86-90.
2. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990;323:645-55.
3. Lam S, Chan H, LeRiche JC, et al. Release of leukotrienes in patients with bronchial asthma. J Allergy Clin Immunol 1988;81:711-7.
4. Manning PJ, Rokach J, Malo JL, et al. Urinary leukotriene E4 levels during early and late asthmatic responses. J Allergy Clin Immunol 1990;86: 211-20.
5. Drazen JM, O'Brien J, Sparrow D, et al. Recovery on leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis 1992; 146:104-8.
6. Manning PJ, Watson RM, Margolskee DJ, et al. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent CYS LT1-receptor antagonist. N Engl J Med 1990;323:1736-9.
7. Margolskee D, Bodman S, Dockhorn R, et al. The therapeutic effects of MK-571, a potent and selective leukotriene (LT) D4 receptor antagonist in patients with chronic asthma [abstract]. J Allergy Clin Immunol 1991;87:309.
8. Taylor IK. Cysteinyl leukotrienes in asthma: current state of therapeutic intervention. Thorax 1995;50:1005-10.
9. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987;136:225-44.
10. Cockcroft DW, Murdock KY, Kirly J, Hargreave FE. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev RespirD is 1987;135:264-67.
11. Juniper E, Cockcroft DW, Hargreave FE. Histamine and methacholine inhalation tests: Tidal breathing method. Laboratory procedure and standardization. Canadian Thoracic Society. AB Draco, Lund, Sweden. 1991:6-29.
12. Srivasta MS, Carter EM. An introduction to applied multivariate statistics. New York: Elsevier Science Publishing Co Inc, 1983:38-57.
13. Chanarin N, Johnston SL. Leukotrienes as a target in asthma therapy. Drugs 1994;47:12-24.
14. Dahlén B, Zetterström O, Björck T, Dahlén SE. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Resp J 1994;7:324-31.
15. Diamant Z, Timmers MC, van der Veen H, et al. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. J Allergy Clin Immunol 1995;95:42-51.
16. Drazen JM, Austen KF. Leukotrienes and airway responses. Am Rev Respir Dis 1987;136:985-98.
17. Busse WW, Gaddy JN. The role of leukotriene antagonists and inhibitors in the treatment of airway disease. Am Rev Respir Dis 1991;143:S103-S107.
18. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996; 98:1-13.